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Aim: Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin family, and 
it promotes the development and function of dopaminergic and serotonergic neurons. The Met 
allele of the BDNF Val66Met polymorphism is associated with a decrease in activity-dependent 
secretion of BDNF compared with the Val allele, and a number of studies have provided evidence 
for the association between this polymorphism and obsessive-compulsive disorder (OCD). The 
purpose of this study was to investigate whether this functional variant of the BDNF gene is asso-
ciated with OCD and treatment response in patients with OCD in the Japanese population.
Methods: We first performed a case–control association study between the BDNF Val66Met 
polymorphism and OCD (175 cases and 2,027 controls). Then, we examined an association 
between this polymorphism and treatment response in 96 patients with OCD.
Results: We found no significant association between the Met allele and OCD risk or between 
the Met allele and treatment responses to selective serotonin reuptake inhibitors or serotonin 
reuptake inhibitor with an atypical antipsychotic (P.0.05).
Conclusion: Our results suggest that the BDNF Val66Met polymorphism may not be associ-
ated as a risk factor for developing OCD or with therapeutic response in patients with OCD in 
the Japanese population.
Keywords: obsessive-compulsive disorder, BDNF, treatment response, association study, 
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Introduction
Obsessive-compulsive disorder (OCD) is a neuropsychiatric disorder with a prevalence 
of ~2%, and it is characterized by repetitive, persistent, intrusive thoughts and repetitive, 
compulsive behaviors.1 Serotonin reuptake inhibitors (SRIs) and antipsychotics are 
used as pharmacological treatments for OCD,2,3 suggesting that changes of serotonergic 
and dopaminergic neurotransmissions may be related to OCD.
Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin family, 
which is known to regulate many aspects of neural circuit development and function, 
including cell proliferation and differentiation, axon and dendrite growth, synaptogenesis, 
and synaptic function and plasticity.4,5 Substantial evidence suggests that BDNF promotes 
the development and function of dopaminergic and serotonergic neurons.6,7 Several 
studies have demonstrated that patients with OCD had significantly decreased plasma 
and serum BDNF levels compared with controls,8–12 and the administration of selective 
SRIs (SSRIs) and atypical antipsychotics enhances BDNF gene expression.6,13
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The BDNF Val66Met polymorphism (rs6265) is a 
functional polymorphism, which affects intracellular pro-
cessing and secretion of BDNF, with the Met allele being 
associated with a decrease in activity-dependent secretion 
of BDNF compared with the Val allele.14,15 This polymor-
phism has been extensively investigated in patients with 
OCD, and a number of studies have provided evidence 
for association between this polymorphism and OCD. 
For example, one family-based association study and four 
case–control studies have demonstrated that the BDNF 
Val66Met polymorphism might be genetically involved in 
the etiology of OCD,16–20 although a recent meta-analysis 
of genetic association studies failed to support these 
findings.21 In addition, several studies have demonstrated 
that the BDNF Val66Met polymorphism was associated 
with clinical characteristics of OCD, such as symptom 
severity, age of onset, family history, poor executive 
functions, and impairments in decision making.16,18,22,23 
Furthermore, the BDNF Val66Met polymorphism was 
associated with treatment response to exposure-based 
cognitive-behavior therapy in patients with OCD,24 and 
a BDNF haplotype, including the BDNF Val66Met poly-
morphism, was associated with treatment response to 
antidepressants in patients with OCD.25
In this study, we hypothesized that the BDNF Val66Met 
polymorphism would be involved in the pathophysiology as 
well as treatment response of OCD in the Japanese popula-
tion. We first performed a case–control association study 
to determine whether the BDNF Val66Met polymorphism 
was genetically implicated in patients with OCD (175 cases 
and 2,027 controls). Then, we investigated whether this 
functional polymorphism was associated with the treatment 
response in 96 patients with OCD.
Subjects and methods
subjects
A total of 175 patients with OCD (82 males and 93 females, 
mean age: 33.7±10.9 years) were recruited from the 
Tokushima University Hospital and Yagoto Hospital in Japan 
in the South Island of Japan (Shikoku) and Yagoto Hospital at 
Middle West in the Mainland of Japan. All patients were of 
Japanese descent. The diagnosis of OCD was made according 
to the Diagnostic and Statistical Manual of Mental Disorders 
(DSM-IV) criteria by at least two expert psychiatrists on the 
basis of extensive clinical interviews and a review of medical 
records. Patients comorbid with other axis I disorders were 
excluded. Among the 175 patients with OCD, 96 patients 
participated in the present pharmacogenetic study. These 
patients were divided into three groups according to the 
treatment response evaluated by the Yale Brown Obsessive-
Compulsive Scale (Y-BOCS) as follows: SSRI (fluvoxamine, 
paroxetine, sertraline, or escitalopram) responders as group 
A (N=56); SSRI with an atypical antipsychotic augmentation 
(risperidone, olanzapine, quetiapine, perospirone, or aripip-
razole) responders as group B (N=23); and nonresponders to 
either SSRI or SSRI with an atypical antipsychotic augmen-
tation as group C (N=17). The treatment responders were 
defined as patients with a reduction in Y-BOCS .35%. 
They were treated in a naturalistic clinical course, and the 
mean follow-up duration was 12.9±8.2 months. Only the 
patients who had no response to SSRI were treated by add-
ing an atypical antipsychotic drug (group B plus C). There 
were no significant differences among the three groups in 
sex, age, onset age, or duration of illness, while significant 
differences were found in Y-BOCS scores at baseline and at 
the end of the treatment (Table 1). Most of these samples were 
used in our previous study.26 The control group comprised 
Table 1 Treatment response group and clinical symptoms of patients with obsessive-compulsive disorder
Group A (N=56) Group B (N=23) Group C (N=17) All patient groups P-value
sex
Male, n (%) 26 (46.4) 13 (56.5) 9 (52.9) 48 (50) 0.69
Female, n (%) 30 (53.6) 10 (43.5) 8 (47.1) 48 (50)
age, mean (sD) 32.86 (12.79) 30.39 (11.07) 28.53 (9.77) 31.5 (11.9) 0.38
Onset age, mean (sD) 24.75 (10.71) 22.74 (12.05) 18.35 (10.94) 23.1 (11.2) 0.12
Duration of illness, mean (sD) 8.11 (9.14) 7.65 (6.29) 10.18 (10.19) 8.4 (8.6) 0.63
Y-BOcs score
Baseline, mean (sD) 23.27 (5.04) 25.57 (4.51) 28.41 (4.43) 24.7 (5.1) 0.001
after treatment, mean (sD) 8.20 (3.86) 11.43 (2.97) 25.53 (4.64) 12.0 (7.4) ,0.001 
Notes: P-values are calculated by χ2 and aNOVa. Duration of illness measured as the length from the onset of obsessive-compulsive disorder to start of the treatment 
in the Tokushima University hospital. group a, responders to ssri; group B, responders to ssri with an atypical antipsychotic; group c, nonresponders to ssri with an 
atypical antipsychotic.
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association between BDNF and clinical response in OcD
2,027 volunteers (855 males and 1,172 females; mean age: 
38.7±13.3 years) recruited from hospital staff, students, and 
company employees who were documented to be free from 
psychiatric problems with no past history of mental illness. 
All of them were of Japanese descent. Details can be seen 
in our previous paper.27 The institutional ethics committee 
of the University of Tokushima Graduate School approved 
the current study and all subjects signed written, informed 
consent forms.
genotyping
We genotyped the BDNF Val66Met polymorphism (rs6265) 
by using a commercially available TaqMan probe with the 
Applied Biosystems 7500 Fast Real Time PCR System and 
followed the protocol recommended by the manufacturer 
(Thermo Fisher Scientific, Waltham, MA, USA).
statistical methods
The association between rs6265 and OCD and the association 
between rs6265 and treatment response in patients with OCD 
were examined using logistic regression under a log-additive 
model. Odds ratio (OR), 95% confidence intervals (CIs), and 
P-value were calculated by using R Version 3.1.2. Power 
calculation was performed using the G*Power 3.1.28
Results
association between rs6265 and OcD
The genotype and allele distributions of rs6265 are shown in 
Table 2. The genotypic distribution of rs6265 did not deviate 
significantly from the Hardy–Weinberg equilibrium in the 
patient group or in the control group (P.0.05). We revealed no 
significant effect of the Met allele on the OCD risk in our sam-
ple set (per-allele OR, 1.05; 95% CI, 0.84–1.31; P=0.68).
association between rs6265 and 
the treatment response in patients 
with OcD
When we compared group A with group B plus C, we did not 
find a significant association between rs6265 and the treatment 
response to SSRI (per-allele OR, 1.43; 95% CI, 0.78–2.59; 
P=0.24). When we compared group B with group C, we did 
not find a significant association between rs6265 and the 
treatment response to SSRI with an antipsychotic medication 
(per-allele OR, 1.28; 95% CI, 0.54–3.03; P=0.57). When 
we compared group A plus B with group C, we did not find 
a significant association between rs6265 and the treatment 
response to SSRI or SSRI with an antipsychotic medication 
(per-allele OR, 1.59; 95% CI, 0.718–3.53; P=0.25).
The power of our sample size for the treatment response 
had 0.27 (group A vs group B plus C), 0.14 (group B vs 
group C), and 0.15 (group A plus B vs group C), respectively, 
for detecting a significant association (α,0.05) when we 
applied an OR of 1.4 in the power calculations.
Discussion
First, we found no significant effect on the Met allele of the 
BDNF Val66Met polymorphism on the OCD risk. This is the 
first association study between the BDNF Val66Met poly-
morphism and OCD conducted on a Japanese population. Our 
finding is consistent with the results of two meta-analyses of 
previous genetic association studies21,29 and with the results of 
two genome-wide association studies.30,31 Zai et al conducted 
a meta-analysis of 13 genetic association studies (five family-
based association studies and eight case–control studies, 
which included Caucasian, Turk, Mexican, and South African 
Afrikaner cohorts), and they found no association between 
the BDNF Val66Met polymorphism and OCD (allele OR, 
1.09; 95% CI, 0.99–1.21; P=0.09).21 Mattheisen et al con-
ducted a genome-wide association studies (N=5,061), and 
they did not find the BDNF Val66Met polymorphism among 
the top 33 single-nucleotide polymorphisms (SNPs) with 
P,1×10−5.30 However, caution must be exercised, because 
the sample size of each association study, including our study, 
was small, and the allele frequency of this polymorphism is 
dependent on ethnic background.32
Second, we demonstrated that the BDNF Val66Met 
polymorphism was not associated with treatment responses 
to SSRI in patients with OCD. This result is consistent with 
the result of a previous pharmacogenetic association study 
of BDNF variants in patients with OCD25 and the result of 
a genome-wide association study of treatment response 
in patients with OCD.33 Real et al compared a group of 
good responders with a group of poor responders to SRIs 
(fluoxetine, fluvoxamine, or clomipramine) in patients 
Table 2 genotype and allele distributions in subjects with obsessive-compulsive disorder and control subjects
Subject group Subjects (n) Val/Val (n) Val/Met (n) Met/Met (n) Val (n) Met (n) HWE OR (95% CI) P-value
OcD 175 59 83 33 201 149 0.69 1.05 (0.84–1.31) 0.68
control 2,027 686 1,002 339 2,374 1,680 0.40 
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with OCD for 12 weeks (N=123), and they did not find a 
significant association between the BDNF Val66Met poly-
morphism and clinical response, although they did reveal 
significant differences between nonresponders and respond-
ers in the haplotype-based analysis of four SNPs (rs1103009, 
rs10501087, rs6265, and rs1491850).25 Qin et al conducted 
a genome-wide association analysis of SRI response in 804 
patients with OCD, and they could not find the BDNF Val66-
Met polymorphism among the top 42 SNPs with P,1×10−4.33 
However, the follow-up periods (12.9 months vs 12 weeks vs 
lack of detailed information), SRI medications, and defini-
tions of treatment response (based on Y-BOCS vs based on 
self-report) differed among these three studies.
Finally, we demonstrated that the BDNF Val66Met 
polymorphism was not associated with treatment response 
to SSRI with an atypical antipsychotic in patients with OCD. 
This is the first pharmacogenetic study to evaluate the effect 
of BDNF Val66Met polymorphism on treatment response to 
SSRI with an atypical antipsychotic in patients with OCD. 
However, our sample size was small, and our patients were 
treated with a variety of SSRI and atypical antipsychotics. 
Further replication studies using larger samples with unified 
medications will be needed.
Conclusion
In conclusion, the BDNF Val66Met polymorphism may not 
be associated as a risk factor for developing OCD or the thera-
peutic responses to SSRI or to SSRI with an atypical antipsy-
chotic, in patients with OCD in the Japanese population.
Acknowledgments
The authors would like to thank all the volunteers who under-
stood our study purpose and participated in this study, and the 
physicians who helped us to collect clinical data and blood 
samples at the mental hospitals. The authors would also like 
to thank Mrs Akemi Okada for her technical assistance. This 
work was supported by Grant-in-Aid for Scientific Research 
(C) (no 26245678).
Author contributions
Drs Numata and Ohmori designed the study and acquired 
the data. Drs Nakaaki, Kinoshita, Sumitani, Watanabe, and 
Umehara acquired the data, and Dr Umehara analyzed the 
data. Dr Umehara wrote the first draft of the manuscript. All 
authors contributed toward data analysis, drafting and criti-
cally revising the paper, gave final approval of the version 
to be published, and agree to be accountable for all aspects 
of the work.
Disclosure
The authors report no conflicts of interest in this work.
References
 1. Ruscio AM, Stein DJ, Chiu WT, Kessler RC. The epidemiology of 
obsessive-compulsive disorder in the National Comorbidity Survey 
Replication. Mol Psychiatry. 2010;15(1):53–63.
 2. Arumugham SS, Reddy JYC. Augmentation strategies in obsessive-
compulsive disorder. Expert Rev Neurother. 2013;13(2):187–202.
 3. Soomro GM, Altman D, Rajagopal S, Oakley-Browne M. Selective 
serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive 
compulsive disorder (OCD). Cochrane Database Syst Rev. 2008;(1): 
CD001765.
 4. Park H, Poo M. Neurotrophin regulation of neural circuit development 
and function. Nat Rev Neurosci. 2013;14(1):7–23.
 5. Pilakka-Kanthikeel S, Atluri VS, Sagar V, Saxena SK, Nair M. Tar-
geted brain derived neurotropic factors (BDNF) delivery across the 
blood-brain barrier for neuro-protection using magnetic nano carriers: 
an in-vitro study. PLoS One. 2013;8(4):e62241.
 6. Martinowich K, Lu B. Interaction between BDNF and serotonin: role 
in mood disorders. Neuropsychopharmacology. 2008;33(1):73–83.
 7. Nurjono M, Lee J, Chong S-A. A review of brain-derived neurotrophic 
factor as a candidate biomarker in schizophrenia. Clin Psychopharmacol 
Neurosci. 2012;10(2):61–70.
 8. Dos Santos IM, Ciulla L, Braga D, et al. Symptom dimensional approach 
and BDNF in unmedicated obsessive-compulsive patients: an explor-
atory study. CNS Spectr. 2011;16(9):179–189.
 9. Fontenelle LF, Barbosa IG, Luna JV, Rocha NP, Silva Miranda A, 
Teixeira AL. Neurotrophic factors in obsessive-compulsive disorder. 
Psychiatry Res. 2012;199(3):195–200.
 10. Maina G, Rosso G, Zanardini R, Bogetto F, Gennarelli M, Bocchio-
Chiavetto L. Serum levels of brain-derived neurotrophic factor in 
drug-naïve obsessive-compulsive patients: a case-control study. J Affect 
Disord. 2010;122(1–2):174–178.
 11. Wang Y, Mathews CA, Li Y, Lin Z, Xiao Z. Brain-derived neurotrophic 
factor (BDNF) plasma levels in drug-naïve OCD patients are lower than 
those in healthy people, but are not lower than those in drug-treated 
OCD patients. J Affect Disord. 2011;133(1–2):305–310.
 12. Wang Y, Zhang H, Li Y, et al. BDNF Val66Met polymorphism and 
plasma levels in Chinese Han population with obsessive-compulsive 
disorder and generalized anxiety disorder. J Affect Disord. 2015; 
186:7–12.
 13. Hill RA, Du X, Wu Y-WC. BDNF–TrkB signaling as a therapeutic 
target in neuropsychiatric disorders. J Receptor Ligand Channel Res. 
2014;7:61.
 14. Chen Z-Y, Patel PD, Sant G, et al. Variant brain-derived neurotrophic 
factor (BDNF) (Met66) alters the intracellular trafficking and activity-
dependent secretion of wild-type BDNF in neurosecretory cells and 
cortical neurons. J Neurosci. 2004;24(18):4401–4411.
 15. Egan MF, Kojima M, Callicott JH, et al. The BDNF val66met poly-
morphism affects activity-dependent secretion of BDNF and human 
memory and hippocampal function. Cell. 2003;112(2):257–269.
 16. Alonso P, Gratacòs M, Menchón JM, et al. Extensive genotyping of the 
BDNF and NTRK2 genes define protective haplotypes against obses-
sive-compulsive disorder. Biol Psychiatry. 2008;63(6):619–628.
 17. Hall D, Dhilla A, Charalambous A, Gogos JA, Karayiorgou M. 
Sequence variants of the brain-derived neurotrophic factor (BDNF) gene 
are strongly associated with obsessive-compulsive disorder. Am J Hum 
Genet. 2003;73(2):370–376.
 18. Hemmings SMJ, Kinnear CJ, Van der Merwe L, et al. Investigating the 
role of the brain-derived neurotrophic factor (BDNF) val66met vari-
ant in obsessive-compulsive disorder (OCD). World J Biol Psychiatry. 
2008;9(2):126–134.
 19. Márquez L, Camarena B, Hernández S, Lóyzaga C, Vargas L, 
Nicolini H. Association study between BDNF gene variants and 







































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Neuropsychiatric Disease and Treatment
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journal
Neuropsychiatric Disease and Treatment is an international, peer-
reviewed journal of clinical therapeutics and pharmacology focusing 
on concise rapid reporting of clinical or pre-clinical studies on a 
range of neuropsychiatric and neurological disorders. This journal 
is indexed on PubMed Central, the ‘PsycINFO’ database and CAS, 
and is the official journal of The International Neuropsychiatric 
 Association (INA). The manuscript management system is completely 
online and includes a very quick and fair peer-review system, which 
is all easy to use. Visit http://www.dovepress.com/testimonials.php to 
read real quotes from published authors.





association between BDNF and clinical response in OcD
 20. Rocha FF, Malloy-Diniz L, Lage NV, Corrêa H. Positive association 
between MET allele (BDNF Val66Met polymorphism) and obsessive-
compulsive disorder. Rev Bras Psiquiatr. 2010;32(3):323–324.
 21. Zai G, Zai CC, Arnold PD, et al. Meta-analysis and association of brain-
derived neurotrophic factor (BDNF) gene with obsessive-compulsive 
disorder. Psychiatr Genet. 2015;25(2):95–96.
 22. Katerberg H, Lochner C, Cath DC, et al. The role of the brain-derived 
neurotrophic factor (BDNF) val66met variant in the phenotypic 
expression of obsessive-compulsive disorder (OCD). Am J Med Genet 
B Neuropsychiatr Genet. 2009;150B(8):1050–1062.
 23. Tükel R, Gürvit H, Ozata B, et al. Brain-derived neurotrophic factor 
gene Val66Met polymorphism and cognitive function in obsessive-
compulsive disorder. Am J Med Genet B Neuropsychiatr Genet. 2012; 
159B(7):850–858.
 24. Fullana MA, Alonso P, Gratacòs M, et al. Variation in the BDNF 
Val66Met polymorphism and response to cognitive-behavior therapy in 
obsessive-compulsive disorder. Eur Psychiatry. 2012;27(5):386–390.
 25. Real E, Gratacòs M, Soria V, et al. A brain-derived neurotrophic 
factor haplotype is associated with therapeutic response in obsessive-
compulsive disorder. Biol Psychiatry. 2009;66(7):674–680.
 26. Umehara H, Numata S, Tajima A, et al. No association between 
the COMT Val158Met polymorphism and the long-term clinical 
response in obsessive-compulsive disorder in the Japanese population. 
Hum Psychopharmacol. 2015;30(5):372–376.
 27. Nishi A, Numata S, Tajima A, et al. Meta-analyses of blood homocysteine 
levels for gender and genetic association studies of the MTHFR 
C677T polymorphism in schizophrenia. Schizophr Bull. 2014;40(5): 
1154–1163.
 28. Faul F, Erdfelder E, Buchner A, Lang A-G. Statistical power analyses 
using G*Power 3.1: tests for correlation and regression analyses. 
Behav Res Methods. 2009;41(4):1149–1160.
 29. Taylor S. Molecular genetics of obsessive-compulsive disorder: a com-
prehensive meta-analysis of genetic association studies. Mol Psychiatry. 
2013;18(7):799–805.
 30. Mattheisen M, Samuels JF, Wang Y, et al. Genome-wide association 
study in obsessive-compulsive disorder: results from the OCGAS. 
Mol Psychiatry. 2015;20(3):337–344.
 31. Stewart SE, Yu D, Scharf JM, et al. Genome-wide association study 
of obsessive-compulsive disorder. Mol Psychiatry. 2013;18(7): 
788–798.
 32. Shimizu E, Hashimoto K, Iyo M. Ethnic difference of the BDNF 
196G/A (val66met) polymorphism frequencies: the possibility to 
explain ethnic mental traits. Am J Med Genet B Neuropsychiatr Genet. 
2004;126B(1):122–123.
 33. Qin H, Samuels JF, Wang Y, et al. Whole-genome association analysis 







































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
